Marinko Marušić
Research Subjects
Research Interests
Marinko Marušić has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Miroslava Katicić
5 shared publications- Ante Bilić4 shared publications
Bruno Skurla
3 shared publications- Dragan Jurcić
Department of Gastroenterology and Hepatology, Internal Clinic, Clinical Hospital Sveti Duh, Sveti Duh 64, 10000, Zagreb, Croatia.
3 shared publications Dragan Schwarz
3 shared publications- Josip Bago
Division of Gastroenterology, Department of Internal Medicine, University Hospital Sveti Duh, Zagreb, Croatia
3 shared publications
Latest Publications
- 1 January 2024
- Published by Springer Nature
- p. 477-508
Acid-Related Disorders
- 14 July 2021
- Published by Wiley in Clinical Endocrinology
- Vol. 96 (2) , 139-143
Hypertriglyceridemia‐induced pancreatitis treated with continuous insulin infusion—Case series
Objective: There are no definitive treatment guidelines for hypertriglyceridemia (HTG)‐induced acute pancreatitis (AP). The aim of this retrospective study was to evaluate the efficacy of insulin in decreasing triglyceride (TG) levels in patients with HTG‐induced AP.Design: We included 17 cases of HTG‐induced AP treated with continuous insulin aspart for 4 days.Patients: Fifteen patients were male, two were female. The mean TG level at admission was 56.53 ± 25.29 mmol/L. The mean APACHE II score was 10.2 ± 5.7, Ranson 4.2 ± 1.7 and Balthazar 6.5 ± 2.6, implying a severe form of the disease.Methods: In an 8‐year period, 17 patients with a diagnosis of HTG‐induced AP were treated with a continuous infusion of 5% dextrose and insulin aspart in an attempt to lower TG levels. TG levels were assessed on admission, the second and fourth day of therapy. The patient outcome, complications and recurrence of AP were monitored.Results: A significant reduction of TG levels was observed in all patients on Day 4. All patients survived, with one forming a giant pseudocyst as a disease complication, one needing haemodialyses treatment due to an acute kidney injury, and one developing acute respiratory distress syndrome that required mechanical ventilation for 4 days. All patients recovered completely.Conclusion: Our study showed that continuous insulin aspart infusion decreases TG levels in HTG‐induced AP from a mean TG level of 56.53 mmol/L on Day 1 to 21.75 mmol/L on Day 2 and finally to 6.86 mmol/L on Day 4. We consider this therapy very efficient, safe, simple to administer and monitor.
- 14 July 2021
- Published by Wiley in Clinical Endocrinology
- Vol. 96 (2) , 139-143
Hypertriglyceridemia‐induced pancreatitis treated with continuous insulin infusion—Case series
Objective: There are no definitive treatment guidelines for hypertriglyceridemia (HTG)‐induced acute pancreatitis (AP). The aim of this retrospective study was to evaluate the efficacy of insulin in decreasing triglyceride (TG) levels in patients with HTG‐induced AP.Design: We included 17 cases of HTG‐induced AP treated with continuous insulin aspart for 4 days.Patients: Fifteen patients were male, two were female. The mean TG level at admission was 56.53 ± 25.29 mmol/L. The mean APACHE II score was 10.2 ± 5.7, Ranson 4.2 ± 1.7 and Balthazar 6.5 ± 2.6, implying a severe form of the disease.Methods: In an 8‐year period, 17 patients with a diagnosis of HTG‐induced AP were treated with a continuous infusion of 5% dextrose and insulin aspart in an attempt to lower TG levels. TG levels were assessed on admission, the second and fourth day of therapy. The patient outcome, complications and recurrence of AP were monitored.Results: A significant reduction of TG levels was observed in all patients on Day 4. All patients survived, with one forming a giant pseudocyst as a disease complication, one needing haemodialyses treatment due to an acute kidney injury, and one developing acute respiratory distress syndrome that required mechanical ventilation for 4 days. All patients recovered completely.Conclusion: Our study showed that continuous insulin aspart infusion decreases TG levels in HTG‐induced AP from a mean TG level of 56.53 mmol/L on Day 1 to 21.75 mmol/L on Day 2 and finally to 6.86 mmol/L on Day 4. We consider this therapy very efficient, safe, simple to administer and monitor.
- Top Cited PapersOpen Access
- 1 January 2021
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2021 (1)
NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2
Nonalcoholic fatty liver disease is a condition defined by fat accumulation in hepatocytes not promoted by excessive alcohol consumption. It is highly prevalent and is strongly associated with insulin resistance, metabolic syndrome, and diabetes type II. Insulin resistance plays a crucial role in the multifactorial etiopathogenesis of this condition leading to accumulation of free fatty acids in the liver cells, thus causing lipotoxicity, inflammation, and fibrosis. In this review, we will focus on currently known pathogenesis of nonalcoholic fatty liver disease. Numerous investigation strategies are available to establish the diagnosis, from biochemical markers and ultrasound to various molecular and advanced imaging techniques and liver biopsy. Prevention is crucial. However, effective and promising therapies are strongly demanded.
- 1 January 2021
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2021 (1)
Top Cited PapersOpen AccessNAFLD, Insulin Resistance, and Diabetes Mellitus Type 2
Nonalcoholic fatty liver disease is a condition defined by fat accumulation in hepatocytes not promoted by excessive alcohol consumption. It is highly prevalent and is strongly associated with insulin resistance, metabolic syndrome, and diabetes type II. Insulin resistance plays a crucial role in the multifactorial etiopathogenesis of this condition leading to accumulation of free fatty acids in the liver cells, thus causing lipotoxicity, inflammation, and fibrosis. In this review, we will focus on currently known pathogenesis of nonalcoholic fatty liver disease. Numerous investigation strategies are available to establish the diagnosis, from biochemical markers and ultrasound to various molecular and advanced imaging techniques and liver biopsy. Prevention is crucial. However, effective and promising therapies are strongly demanded.
- 12 June 2018
- Published by Springer Nature
- p. 191-201
Treatment
- 12 June 2018
- Published by Springer Nature
- p. 145-161
Anorectal Function
- 1 April 2018
- Vol. 81 (2) , 305-317
Gastroesophageal variceal bleeding - An overview of current treatment options
Gastroesophageal variceal hemorrhage is the most important clinical event that results from portal hypertension. It is a lifethreatening condition that demands rapid and efficient treatment. The first step in bleeding control is hemodynamic stabilization and pharmacological treatment, which includes administration of vasoactive drugs and short-term antibiotic prophylaxis. After initial hemodynamic stabilization, endoscopic therapy should be performed. The first choice of endoscopic treatment for esophageal bleeding is endoscopic variceal ligation (EVL), or endoscopic injection sclerotherapy (EIS) if EVL cannot be performed. Several rescue therapies, such as application of balloon tamponade, a self-expandable metal stent (SEMS), or a transjugular intrahepatic portosystemic shunt (TIPS), are available in cases of resistant variceal bleeding that cannot be controlled with endoscopic therapies. Gastric varices have a lower incidence than esophageal varices, but bleeding from gastric varices is associated with higher mortality and morbidity rates. The first-line treatment, as with esophageal variceal bleeding, is stabilization of the patient. After that, control of bleeding can be attempted. Optimal management of gastric variceal bleeding is not yet standardized due to diverse underlying pathologies and the lack of large, randomized controlled trials. Among endoscopic techniques, endoscopic variceal obturation (EVO) has been acknowledged as reliable. Among rescue therapies, balloon-occluded retrograde transvenous obliteration (B-RTO) of gastric varices and TIPS are the most common techniques.
- 1 April 2018
- Vol. 81 (2) , 305-317
Gastroesophageal variceal bleeding - An overview of current treatment options
Gastroesophageal variceal hemorrhage is the most important clinical event that results from portal hypertension. It is a lifethreatening condition that demands rapid and efficient treatment. The first step in bleeding control is hemodynamic stabilization and pharmacological treatment, which includes administration of vasoactive drugs and short-term antibiotic prophylaxis. After initial hemodynamic stabilization, endoscopic therapy should be performed. The first choice of endoscopic treatment for esophageal bleeding is endoscopic variceal ligation (EVL), or endoscopic injection sclerotherapy (EIS) if EVL cannot be performed. Several rescue therapies, such as application of balloon tamponade, a self-expandable metal stent (SEMS), or a transjugular intrahepatic portosystemic shunt (TIPS), are available in cases of resistant variceal bleeding that cannot be controlled with endoscopic therapies. Gastric varices have a lower incidence than esophageal varices, but bleeding from gastric varices is associated with higher mortality and morbidity rates. The first-line treatment, as with esophageal variceal bleeding, is stabilization of the patient. After that, control of bleeding can be attempted. Optimal management of gastric variceal bleeding is not yet standardized due to diverse underlying pathologies and the lack of large, randomized controlled trials. Among endoscopic techniques, endoscopic variceal obturation (EVO) has been acknowledged as reliable. Among rescue therapies, balloon-occluded retrograde transvenous obliteration (B-RTO) of gastric varices and TIPS are the most common techniques.
- 1 April 2017
- Published by Edizioni Minerva Medica in Minerva Gastroenterology
- Vol. 63 (2) , 80-84
Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication
Article: Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication - Minerva Gastroenterologica e Dietologica 2017 June;63(2):80-4 - Minerva Medica - Journals
- 1 April 2017
- Published by Edizioni Minerva Medica in Minerva Gastroenterology
- Vol. 63 (2) , 80-84
Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication
Article: Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication - Minerva Gastroenterologica e Dietologica 2017 June;63(2):80-4 - Minerva Medica - Journals
- 2 March 2017
- Published by Springer Nature in Inflammopharmacology
- Vol. 25 (2) , 255-264
Cyclophosphamide induced stomach and duodenal lesions as a NO-system disturbance in rats: l-NAME, l-arginine, stable gastric pentadecapeptide BPC 157
We revealed a new point with cyclophosphamide (150 mg/kg/day intraperitoneally for 7 days): we counteracted both rat stomach and duodenal ulcers and increased NO- and MDA-levels in these tissues. As a NO-system effect, BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once a day or in drinking water, till the sacrifice) attenuated the increased NO- and MDA-levels and nullified, in rats, severe cyclophosphamide-ulcers and even stronger stomach and duodenal lesions after cyclophosphamide + l-NAME (5 mg/kg intraperitoneally once a day). l-arginine (100 mg/kg intraperitoneally once a day not effective alone) led l-NAME-values only to the control values (cyclophosphamide + l-NAME + l-arginine-rats). Briefly, rats were sacrificed at 24 h after last administration on days 1, 2, 3, or 7, and assessment included sum of longest lesions diameters (mm) in the stomach and duodenum, oxidative stress by quantifying thiobarbituric acid reactivity as malondialdehyde equivalents (MDA), NO in stomach and duodenal tissue samples using the Griess reaction. All these parameters were highly exaggerated in rats who underwent cyclophosphamide treatment. We identified high MDA-tissue values, high NO-tissue values, ulcerogenic and beneficial potential in cyclophosphamide-l-NAME-l-arginine-BPC 157 relationships. This suggests that in cyclophosphamide damaged rats, NO excessive release generated by the inducible isozyme, damages the vascular wall and other tissue cells, especially in combination with reactive oxygen intermediates, while failing endothelial production and resulting in further aggravation by l-NAME which was inhibited by l-arginine. Finally, BPC 157, due to its special relations with NO-system, may both lessen increased MDA- and NO-tissues values and counteract effects of both cyclophosphamide and l-NAME on stomach and duodenal lesions.
- 2 March 2017
- Published by Springer Nature in Inflammopharmacology
- Vol. 25 (2) , 255-264
Cyclophosphamide induced stomach and duodenal lesions as a NO-system disturbance in rats: l-NAME, l-arginine, stable gastric pentadecapeptide BPC 157
We revealed a new point with cyclophosphamide (150 mg/kg/day intraperitoneally for 7 days): we counteracted both rat stomach and duodenal ulcers and increased NO- and MDA-levels in these tissues. As a NO-system effect, BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once a day or in drinking water, till the sacrifice) attenuated the increased NO- and MDA-levels and nullified, in rats, severe cyclophosphamide-ulcers and even stronger stomach and duodenal lesions after cyclophosphamide + l-NAME (5 mg/kg intraperitoneally once a day). l-arginine (100 mg/kg intraperitoneally once a day not effective alone) led l-NAME-values only to the control values (cyclophosphamide + l-NAME + l-arginine-rats). Briefly, rats were sacrificed at 24 h after last administration on days 1, 2, 3, or 7, and assessment included sum of longest lesions diameters (mm) in the stomach and duodenum, oxidative stress by quantifying thiobarbituric acid reactivity as malondialdehyde equivalents (MDA), NO in stomach and duodenal tissue samples using the Griess reaction. All these parameters were highly exaggerated in rats who underwent cyclophosphamide treatment. We identified high MDA-tissue values, high NO-tissue values, ulcerogenic and beneficial potential in cyclophosphamide-l-NAME-l-arginine-BPC 157 relationships. This suggests that in cyclophosphamide damaged rats, NO excessive release generated by the inducible isozyme, damages the vascular wall and other tissue cells, especially in combination with reactive oxygen intermediates, while failing endothelial production and resulting in further aggravation by l-NAME which was inhibited by l-arginine. Finally, BPC 157, due to its special relations with NO-system, may both lessen increased MDA- and NO-tissues values and counteract effects of both cyclophosphamide and l-NAME on stomach and duodenal lesions.
- Open Access
- 1 January 2017
- Published by Sestre Milosrdnice University Hospital Center (KBC Sestre milosrdnice) in Acta Clinica Croatica
- Vol. 56. (1.) , 179-182
Common Bile Duct Stricture After Laparoscopic Cholecystectomy: Case Report
Despite progress in laparoscopic surgery and increasing surgical experience, the incidence of bile duct injury during laparoscopic cholecystectomy fails to fall below 0.3%-0.6% and it is still higher than those recorded in the era of...
- 1 January 2017
- Published by Sestre Milosrdnice University Hospital Center (KBC Sestre milosrdnice) in Acta Clinica Croatica
- Vol. 56. (1.) , 179-182
Open AccessCommon Bile Duct Stricture After Laparoscopic Cholecystectomy: Case Report
Despite progress in laparoscopic surgery and increasing surgical experience, the incidence of bile duct injury during laparoscopic cholecystectomy fails to fall below 0.3%-0.6% and it is still higher than those recorded in the era of...
- Open Access
- 1 January 2017
- Published by Sestre Milosrdnice University Hospital Center (KBC Sestre milosrdnice) in Acta Clinica Croatica
- Vol. 56 (2.) , 344-348
What is the Right Therapeutic Approach to Biliary Choledochal Cyst?
We report a case of biliary cyst type II which, independently of its a priori benign nature, caused numerous complications such as recurrent cholangitis and pancreatitis, as well as subsequent hepatic fibrosis and the potential danger of...
- 1 January 2017
- Published by Sestre Milosrdnice University Hospital Center (KBC Sestre milosrdnice) in Acta Clinica Croatica
- Vol. 56 (2.) , 344-348
Open AccessWhat is the Right Therapeutic Approach to Biliary Choledochal Cyst?
We report a case of biliary cyst type II which, independently of its a priori benign nature, caused numerous complications such as recurrent cholangitis and pancreatitis, as well as subsequent hepatic fibrosis and the potential danger of...